Telomerase peptide vaccination: a phase I/II study in pa cancer

Cancer Immunology, Immunotherapy

55, 1553-1564

DOI: 10.1007/s00262-006-0145-7

Citation Report

#	Article	IF	Citations
1	Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells. Cancer Immunology, Immunotherapy, 2006, 55, 1432-1442.	2.0	78
2	Telomerase therapeutics for cancer: challenges and new directions. Nature Reviews Drug Discovery, 2006, 5, 577-584.	21.5	375
3	Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study. British Journal of Cancer, 2006, 95, 1474-1482.	2.9	260
4	Telomerase-based immunotherapy of cancer. Expert Opinion on Biological Therapy, 2006, 6, 1031-1039.	1.4	26
5	Vaccination of Patients With Advanced Nonâ€“Small-Cell Lung Cancer With an Optimized Cryptic Human Telomerase Reverse Transcriptase Peptide. Journal of Clinical Oncology, 2007, 25, 2727-2734.	0.8	95
6	Lung Cancer Vaccines. Current Gene Therapy, 2007, 7, 469-484.	0.9	5
7	A review of vaccine clinical trials for non-small cell lung cancer. Expert Opinion on Biological Therapy, 2007, 7, 89-102.	1.4	14
8	Universal and Stemness-Related Tumor Antigens: Potential Use in Cancer Immunotherapy. Clinical Cancer Research, 2007, 13, 5675-5679.	3.2	32
9	Energetics of Quadruplex-Drug Recognition in Anticancer Therapy. Current Cancer Drug Targets, 2007, 7, 520-540.	0.8	36
10	The HLA A*0201â€“restricted hTERT540â€“548 peptide is not detected on tumor cells by a CTL clone or a high-affinity T-cell receptor. Molecular Cancer Therapeutics, 2007, 6, 2081-2091.	1.9	48
11	Fast, hungry and unstable: finding the Achillesâ€™ heel of small-cell lung cancer. Trends in Molecular Medicine, 2007, 13, 150-157.	3.5	29
12	Current Immunotherapeutic Strategies in Lung Cancer. Surgical Oncology Clinics of North America, 2007, 16, 901-918.	0.6	7
13	Telomerase immunity from bench to bedside: round one. Journal of Translational Medicine, 2007, 5, 12.	1.8	36
14	Current state of immunotherapy for non-small cell lung cancer. Translational Lung Cancer Research, 2007, 6, 196-211.	1.3	150
15	Hallmarks of telomeres in ageing research. Journal of Pathology, 2007, 211, 114-123.	2.1	185
16	Telomerase and its potential for therapeutic intervention. British Journal of Pharmacology, 2007, 152, 1003-1011.	2.7	78
17	Role of telomeres and telomerase in genomic instability, senescence and cancer. Laboratory Investigation, 2007, 87, 1071-1076.	1.7	85
18	Telomerase (hTERT 611â€“626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells. Experimental Hematology, 2007, 35, 297-304.	0.2	50

#	Article	IF	Citations
19	Telomeres and telomerase as targets for cancer therapy. Cellular and Molecular Life Sciences, 2007, 64, 906-921.	2.4	56
20	T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells. Cancer Immunology, Immunotherapy, 2007, 56, 659-675.	2.0	60
21	Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers. Cancer Immunology, Immunotherapy, 2007, 56, 1485-1499.	2.0	85
22	Vaccine therapy in nonâ€"small-cell lung cancer. Current Oncology Reports, 2007, 9, 241-246.	1.8	6
23	Recent advances in the development of novel antiâ€cancer drugs targeting cancer stem/progenitor cells. Drug Development Research, 2008, 69, 415-430.	1.4	17
24	Targeting telomerase for cancer therapeutics. British Journal of Cancer, 2008, 98, 677-683.	2.9	149
25	Telomerase and cancer therapeutics. Nature Reviews Cancer, 2008, 8, 167-179.	12.8	635
26	Immune Modulation as a Therapeutic Strategy for Nonâ€"Small-Cell Lung Cancer. Clinical Lung Cancer, 2008, 9, S13-S19.	1.1	11
28	Prospects and challenges of building a cancer vaccine targeting telomerase. Biochimie, 2008, 90, 173-180.	1.3	50
29	Targeting telomeres and telomerase. Biochimie, 2008, 90, 131-155.	1.3	538
30	Telomerase as a universal tumor antigen for cancer vaccines. Expert Review of Vaccines, 2008, 7, 881-887.	2.0	57
31	Targeted therapies for pancreatic cancer. British Medical Bulletin, 2008, 87, 97-130.	2.7	26
32	Cancer Therapeutics: Emerging Targets and Trends. Current Cancer Therapy Reviews, 2008, 4, 50-56.	0.2	1
33	Co-expression patterns of tumor-associated antigen genes by non-small cell lung carcinomas: Implications for immunotherapy. Cancer Biology and Therapy, 2008, 7, 345-352.	1.5	20
34	Cutaneous delivery of prophylactic and therapeutic vaccines: historical perspective and future outlook. Expert Review of Vaccines, 2008, 7, 1329-1339.	2.0	44
35	The Immunogenicity of the hTERT540-548 Peptide in Cancer. Clinical Cancer Research, 2008, 14, 4-7.	3.2	42
36	Lung Cancer Vaccine Therapy. Japanese Journal of Lung Cancer, 2009, 49, 823-830.	0.0	0
37	Multipeptide vaccination in cancer patients. Expert Opinion on Biological Therapy, 2009, 9, 1043-1055.	1.4	57

#	Article	IF	Citations
38	Unconventional cytokine profiles and development of T cell memory in long-term survivors after cancer vaccination. Cancer Immunology, Immunotherapy, 2009, 58, 1609-1626.	2.0	44
39	The functioning antigens: beyond just as the immunological targets. Cancer Science, 2009, 100, 798-806.	1.7	38
40	Novel spliced form of a lens protein as a novel lung cancer antigen, Lengsin splicing variantÂ4. Cancer Science, 2009, 100, 1485-1493.	1.7	30
41	Cancer vaccination with telomerase peptide GV1001. Expert Opinion on Investigational Drugs, 2009, 18, 687-694.	1.9	70
42	Prostate tumor-initiating cells: A new target for telomerase inhibition therapy?. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2009, 1792, 289-296.	1.8	28
43	Recent insights into the molecular mechanisms involved in aging and the malignant transformation of adult stem/progenitor cells and their therapeutic implications. Ageing Research Reviews, 2009, 8, 94-112.	5.0	75
44	Active specific immunotherapy and cell-transfer therapy for the treatment of non-small cell lung cancer. Lung Cancer, 2009, 65, 1-8.	0.9	25
45	Telomere Dysfunction and DNA Damage Checkpoints in Diseases and Cancer of the Gastrointestinal Tract. Gastroenterology, 2009, 137, 754-762.	0.6	25
46	Generation in vivo of peptide-specific cytotoxic T cells and presence of regulatory T cells during vaccination with hTERT (class I and II) peptide-pulsed DCs. Journal of Translational Medicine, 2009, 7, 18.	1.8	23
48	Potential Molecular Therapeutic Targets in Cancer Stem/Progenitor Cells: Are ATP-Binding Cassette Membrane Transporters Appropriate Targets to Eliminate Cancer-Initiating Cells?. , 2009, , 385-421.		0
49	Localization of telomerase hTERT protein in frozen sections of basal cell carcinomas (BCC) and tumor margin tissues. International Journal of Oncology, 2009, 35, 1377-94.	1.4	3
50	Targeting Cancer Stem Cells: How to Switch Off Immortality. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, 2009, 3, 225-232.	0.7	0
51	Telomerase in cancer immunotherapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2010, 1805, 35-42.	3.3	38
52	Telomeres and telomerase in normal and malignant Bâ€cells. Hematological Oncology, 2010, 28, 157-167.	0.8	14
53	MHC II lung cancer vaccines prime and boost tumorâ€specific CD4⁺ T cells that crossâ€react with multiple histologic subtypes of nonsmall cell lung cancer cells. International Journal of Cancer, 2010, 127, 2612-2621.	2.3	18
54	ãƒ†ãƒãƒ¡ã,¢ãƒ»ãƒ†ãƒãƒ¡ãƒ¬ãƒ¼ãƒ¼ã,¹ã,'æ¨™çš„ã•ã•—ãŸæŠ—è…«ç˜ç™,æ³•. Kagaku To Seibutsu, 2010, 48, 713-719.	0.0	0
55	Current status of GV1001 and other telomerase vaccination strategies in the treatment of cancer. Expert Review of Vaccines, 2010, 9, 1007-1016.	2.0	33
56	Current vaccine updates for lung cancer. Expert Review of Vaccines, 2010, 9, 323-335.	2.0	6

#	Article	IF	Citations
57	Telomerase as a Target for Cancer Therapeutics. , 2010, , 231-249.		2
58	Telomere-Based Cancer Treatment. Clinical Journal of Oncology Nursing, 2010, 14, 720-726.	0.3	2
59	A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. BMC Cancer, 2010, 10, 209.	1.1	174
60	215 A PHASE II OPEN LABEL TRIAL EVALUATING SAFETY AND EFFICACY OF A TELOMERASE PEPTIDE VACCINATION IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA. Journal of Hepatology, 2010, 52, S92.	1.8	1
62	Gene-Based Therapies for Cancer. , 2010, , .		0
63	Telomerase Peptide Vaccination in NSCLC: A Phase II Trial in Stage III Patients Vaccinated after Chemoradiotherapy and an 8-Year Update on a Phase I/II Trial. Clinical Cancer Research, 2011, 17, 6847-6857.	3.2	149
64	Telomerase-specific GV1001 peptide vaccination fails to induce objective tumor response in patients with cutaneous T cell lymphoma. Journal of Dermatological Science, 2011, 62, 75-83.	1.0	22
65	Cancer, Senescence, and Aging: Translation from Basic Research to Clinics. Journal of Aging Research, 2011, 2011, 1-2.	0.4	1
66	Cancer Vaccines in Phase II/III Clinical Trials: State of the Art and Future Perspectives. Current Cancer Drug Targets, 2011, 11, 85-102.	0.8	27
67	Targeting telomerase-expressing cancer cells. Journal of Cellular and Molecular Medicine, 2011, 15, 1433-1442.	1.6	69
68	Chemistry in human telomere biology: structure, function and targeting of telomere DNA/RNA. Chemical Society Reviews, 2011, 40, 2719.	18.7	287
69	hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes. Cancer Immunology, Immunotherapy, 2011, 60, 809-818.	2.0	85
70	Vaccination of patients with cutaneous melanoma with telomerase-specific peptides. Cancer Immunology, Immunotherapy, 2011, 60, 1553-1564.	2.0	42
71	Antitumor effects of telomerase inhibitor TMPyP4 in osteosarcoma cell lines. Journal of Orthopaedic Research, 2011, 29, 1707-1711.	1.2	33
72	Telomerase Peptide Vaccination Combined with Temozolomide: A Clinical Trial in Stage IV Melanoma Patients. Clinical Cancer Research, 2011, 17, 4568-4580.	3.2	105
73	Regulation of Senescence in Cancer and Aging. Journal of Aging Research, 2011, 2011, 1-15.	0.4	51
74	Current Immunotherapeutic Approaches in Pancreatic Cancer. Clinical and Developmental Immunology, 2011, 2011, 1-15.	3.3	66
75	Vaccines as consolidation therapy for myeloid leukemia. Expert Review of Hematology, 2011, 4, 37-50.	1.0	17

#	Article	IF	Citations
76	Immunotherapy as a strategy for the treatment of non-small-cell lung cancer. Therapy: Open Access in Clinical Medicine, 2011, 8, 43-54.	0.2	53
77	Widespread CD4+ T-cell reactivity to novel hTERT epitopes following vaccination of cancer patients with a single hTERT peptide GV1001. OncoImmunology, 2012, 1, 670-686.	2.1	95
78	Clinical outcome of patients with various advanced cancer types vaccinated with an optimized cryptic human telomerase reverse transcriptase (TERT) peptide: results of an expanded phase II study. Annals of Oncology, 2012, 23, 442-449.	0.6	45
79	Trial watch. OncoImmunology, 2012, 1, 1557-1576.	2.1	110
80	Discovering Drug Targets for Cancer Therapy. , 2012, , 299-322.		0
81	Myeloid dendritic cells loaded with dendritic tandem multiple antigenic telomerase reverse transcriptase (hTERT) epitope peptides: A potentially promising tumor vaccine. Vaccine, 2012, 30, 3395-3404.	1.7	4
82	Expression of chondroitinâ€glucuronate C5â€epimerase and cellular immune responses in patients with hepatocellular carcinoma. Liver International, 2012, 32, 1516-1526.	1.9	14
84	Is telomerase a viable target in cancer?. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2012, 730, 90-97.	0.4	117
85	Heat shock protein-mediated cell penetration and cytosolic delivery ofÂmacromolecules by a telomerase-derived peptide vaccine. Biomaterials, 2013, 34, 7495-7505.	5.7	34
86	A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer. Cancer Immunology, Immunotherapy, 2013, 62, 1041-1052.	2.0	55
87	Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer. Seminars in Immunology, 2013, 25, 182-190.	2.7	44
88	Novel anticancer therapeutics targeting telomerase. Cancer Treatment Reviews, 2013, 39, 444-456.	3.4	269
89	The Role of Telomere Biology in Cancer. Annual Review of Pathology: Mechanisms of Disease, 2013, 8, 49-78.	9.6	118
90	Characterization of CD8⁺T-Cell Responses in the Peripheral Blood and Skin Injection Sites of Melanoma Patients Treated with mRNA Electroporated Autologous Dendritic Cells (TriMixDC-MEL). BioMed Research International, 2013, 2013, 1-8.	0.9	38
91	Cancer targeting vaccines:Â Surrogate measures of activity. Human Vaccines and Immunotherapeutics, 2013, 9, 213-218.	1.4	1
92	Trial Watch. OncoImmunology, 2013, 2, e26621.	2.1	101
93	Development of a novel redirected T-cellâ€“based adoptive immunotherapy targeting human telomerase reverse transcriptase for adult T-cell leukemia. Blood, 2013, 121, 4894-4901.	0.6	40
95	Clinical implications of antitelomeric drugs with respect to the nontelomeric functions of telomerase in cancer. OncoTargets and Therapy, 2013, 6, 1161.	1.0	10

#	Article	IF	Citations
96	Telomerase: target for cancer treatment. , 0, , 442-451.		0
97	Telomere Maintenance Mechanisms in Cancer: Clinical Implications. Current Pharmaceutical Design, 2014, 20, 6361-6374.	0.9	74
98	Peptide Vaccine: Progress and Challenges. Vaccines, 2014, 2, 515-536.	2.1	518
99	Recent progress in peptide vaccination in cancer with a focus on non-small-cell lung cancer. Expert Review of Vaccines, 2014, 13, 87-116.	2.0	3
100	Overexpressed oncogenic tumor-self antigens. Human Vaccines and Immunotherapeutics, 2014, 10, 3297-3305.	1.4	48
101	New Approaches in Immunotherapy for the Treatment of Lung Cancer. Current Topics in Microbiology and Immunology, 2014, 405, 1-31.	0.7	9
102	The novel vaccine peptide GV1001 effectively blocks Î²-amyloid toxicity by mimicking the extra-telomeric functions of human telomerase reverse transcriptase. Neurobiology of Aging, 2014, 35, 1255-1274.	1.5	55
103	A phase II trial evaluating the clinical and immunologic response of HLA-A2+ non-small cell lung cancer patients vaccinated with an hTERT cryptic peptide. Lung Cancer, 2014, 86, 59-66.	0.9	50
104	Evaluation of Biocompatibility of the AC8 Peptide and Its Potential Use as a Drug Carrier. Molecular Pharmaceutics, 2014, 11, 3409-3420.	2.3	7
105	Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. Lancet Oncology, The, 2014, 15, 829-840.	5.1	296
106	Protective Effect of Peptide GV1001 Against Renal Ischemia-Reperfusion Injury in Mice. Transplantation Proceedings, 2014, 46, 1117-1122.	0.3	24
107	Tumor-suppressive effect of a telomerase-derived peptide by inhibiting hypoxia-induced HIF-1Î±-VEGF signaling axis. Biomaterials, 2014, 35, 2924-2933.	5.7	24
108	miR-1207-5p and miR-1266 suppress gastric cancer growth and invasion by targeting telomerase reverse transcriptase. Cell Death and Disease, 2014, 5, e1034-e1034.	2.7	118
109	Telomerase (GV1001) vaccination together with gemcitabine in advanced pancreatic cancer patients. International Journal of Oncology, 2014, 45, 1293-1303.	1.4	56
110	Composite peptide-based vaccines for cancer immunotherapy (Review). International Journal of Molecular Medicine, 2015, 35, 17-23.	1.8	16
111	Immunological features of T cells induced by human telomerase reverse transcriptase-derived peptides in patients with hepatocellular carcinoma. Cancer Letters, 2015, 364, 98-105.	3.2	31
112	Multi-Targeted Approach to Treatment of Cancer. , 2015, , .		1
113	Peptide Immunotherapy in Vaccine Development. Advances in Protein Chemistry and Structural Biology, 2015, 99, 1-14.	1.0	31

#	Article	IF	Citations
114	Vaccine therapy in NSCLC: a review. Lung Cancer Management, 2015, 4, 31-41.	1.5	1
115	Macrocyclic naphthalene diimides as G-quadruplex binders. Bioorganic and Medicinal Chemistry, 2015, 23, 3819-3830.	1.4	34
116	Immunogenicity of GX301 cancer vaccine: Four (telomerase peptides) are better than one. Human Vaccines and Immunotherapeutics, 2015, 11, 838-850.	1.4	26
117	Immunological factors influencing clinical outcome in lung cancer patients after telomerase peptide vaccination. Cancer Immunology, Immunotherapy, 2015, 64, 1609-1621.	2.0	42
118	Therapeutic inhibition of <scp>TRF</scp> 1 impairs the growth of p53 â€deficient Kâ€Ras ^{G12V} â€ induced lung cancer by induction of telomeric <scp>DNA</scp> damage. EMBO Molecular Medicine, 2015, 7, 930-949.	3.3	45
119	Phase I trial of multidrug resistance-associated protein 3-derived peptide in patients with hepatocellular carcinoma. Cancer Letters, 2015, 369, 242-249.	3.2	37
120	Annexin A3 as a Potential Target for Immunotherapy of Liver Cancer Stem-Like Cells. Stem Cells, 2015, 33, 354-366.	1.4	54
121	Therapeutic Targeting of Telomerase. Genes, 2016, 7, 39.	1.0	109
122	Telomere and Telomerase Therapeutics in Cancer. Genes, 2016, 7, 22.	1.0	85
123	The Telomerase-Derived Anticancer Peptide Vaccine GV1001 as an Extracellular Heat Shock Protein-Mediated Cell-Penetrating Peptide. International Journal of Molecular Sciences, 2016, 17, 2054.	1.8	33
124	Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies. Genome Medicine, 2016, 8, 69.	3.6	470
125	Mechanistic understanding and significance of small peptides interaction with <scp>MHC</scp> class <scp>II</scp> molecules for therapeutic applications. Immunological Reviews, 2016, 272, 151-168.	2.8	16
126	T-helper cell receptors from long-term survivors after telomerase cancer vaccination for use in adoptive cell therapy. OncoImmunology, 2016, 5, e1249090.	2.1	16
127	Feasibility of Telomerase-Specific Adoptive T-cell Therapy for B-cell Chronic Lymphocytic Leukemia and Solid Malignancies. Cancer Research, 2016, 76, 2540-2551.	0.4	25
128	Inhibition of HIV-1 reactivation by a telomerase-derived peptide in a HSP90-dependent manner. Scientific Reports, 2016, 6, 28896.	1.6	29
129	Immunologic approaches to cancer preventionâ€"current status, challenges, and future perspectives. Seminars in Oncology, 2016, 43, 161-172.	0.8	35
130	A second chance for telomerase reverse transcriptase in anticancer immunotherapy. Nature Reviews Clinical Oncology, 2017, 14, 115-128.	12.5	95
132	Immune responses and longâ€term disease recurrence status after telomeraseâ€based dendritic cell immunotherapy in patients with acute myeloid leukemia. Cancer, 2017, 123, 3061-3072.	2.0	68

#	Article	IF	Citations
133	Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer. Cancer Immunology, Immunotherapy, 2017, 66, 891-901.	2.0	71
134	GV1001 immunotherapy ameliorates joint inflammation in a murine model of rheumatoid arthritis by modifying collagen-specific T-cell responses and downregulating antigen-presenting cells. International Immunopharmacology, 2017, 46, 186-193.	1.7	2
135	T cell therapy targeting a public neoantigen in microsatellite instable colon cancer reducesin vivotumor growth. OncoImmunology, 2017, 6, e1302631.	2.1	57
136	Telomerase based anticancer immunotherapy and vaccines approaches. Vaccine, 2017, 35, 5768-5775.	1.7	25
137	Protective effects of GV1001 on myocardial ischemia-reperfusion injury. Molecular Medicine Reports, 2017, 16, 7315-7320.	1.1	7
138	New vaccination strategies in liver cancer. Cytokine and Growth Factor Reviews, 2017, 36, 125-129.	3.2	20
139	Multi Epitope Peptide Vaccine Prediction against Sudan Ebola Virus Using Immuno-Informatics Approaches. Advanced Techniques in Biology & Medicine, 2017, 05, .	0.1	9
140	Indoleamine 2,3-dioxygenase and survivin peptide vaccine combined with temozolomide in metastatic melanoma. Stem Cell Investigation, 2017, 4, 77-77.	1.3	22
141	GV1001 Induces Apoptosis by Reducing Angiogenesis in Renal Cell Carcinoma Cells Both In Vitro and In Vivo. Urology, 2018, 113, 129-137.	0.5	8
142	Peptide based therapeutics and their use for the treatment of neurodegenerative and other diseases. Biomedicine and Pharmacotherapy, 2018, 103, 574-581.	2.5	85
143	Correlates of immune and clinical activity of novel cancer vaccines. Seminars in Immunology, 2018, 39, 119-136.	2.7	54
144	hTERT peptide fragment GV1001 demonstrates radioprotective and antifibrotic effects through suppression of TGFâ€Î² signaling. International Journal of Molecular Medicine, 2018, 41, 3211-3220.	1.8	8
145	The Novel Peptide Vaccine GV1001 Protects Hearing in a Kanamycin-induced Ototoxicity Mouse Model. Otology and Neurotology, 2018, 39, e731-e737.	0.7	9
146	A peptide-CpG-DNA-liposome complex vaccine targeting TM4SF5 suppresses growth of pancreatic cancer in a mouse allograft model. OncoTargets and Therapy, 2018, Volume 11, 8655-8672.	1.0	12
147	Emerging immunotherapeutic strategies targeting telomerases in genitourinary tumors. Critical Reviews in Oncology/Hematology, 2018, 131, 1-6.	2.0	10
148	An overview of cancer immunotherapeutic strategies. Immunotherapy, 2018, 10, 999-1010.	1.0	26
149	Novel Peptide Vaccine GV1001 Rescues Hearing in Kanamycin/Furosemide-Treated Mice. Frontiers in Cellular Neuroscience, 2018, 12, 3.	1.8	12
150	Peptides in immunoengineering. , 2018, , 287-326.		3

#	Article	IF	Citations
151	Transient redirection of T cells for adoptive cell therapy with telomerase-specific T helper cell receptors isolated from long term survivors after cancer vaccination. OncoImmunology, 2019, 8, e1565236.	2.1	7
152	In silico rational design of a novel tetra-epitope tetanus vaccine with complete population coverage using developed immunoinformatics and surface epitope mapping approaches. Medical Hypotheses, 2019, 130, 109267.	0.8	3
153	Systemic Management for Advanced Hepatocellular Carcinoma: A Review of the Molecular Pathways of Carcinogenesis, Current and Emerging Therapies, and Novel Treatment Strategies. Digestive Diseases and Sciences, 2019, 64, 1016-1029.	1.1	25
154	Telomerase-Targeted Cancer Immunotherapy. International Journal of Molecular Sciences, 2019, 20, 1823.	1.8	80
155	GV1001 inhibits cell viability and induces apoptosis in castration-resistant prostate cancer cells through the AKT/NF-Î°B/VEGF pathway. Journal of Cancer, 2019, 10, 6269-6277.	1.2	10
156	Molecular identification of telomerase reverse transcriptase (TERT) promotor mutations in primary and recurrent tumors of invasive and noninvasive urothelial bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 77.e17-77.e25.	0.8	12
157	Therapeutic strategies for targeting telomerase in cancer. Medicinal Research Reviews, 2020, 40, 532-585.	5.0	38
158	Nanotechnology platforms for cancer immunotherapy. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2020, 12, e1590.	3.3	82
159	Long-term surviving cancer patients as a source of therapeutic TCR. Cancer Immunology, Immunotherapy, 2020, 69, 859-865.	2.0	16
160	A telomerase-derived peptide vaccine inhibits laser-induced choroidal neovascularization in a rat model. Translational Research, 2020, 216, 30-42.	2.2	0
161	Role of Telomeres and Telomeric Proteins in Human Malignancies and Their Therapeutic Potential. Cancers, 2020, 12, 1901.	1.7	34
162	The secrets of telomerase: Retrospective analysis and future prospects. Life Sciences, 2020, 257, 118115.	2.0	11
163	Telomerase and CD4 T Cell Immunity in Cancer. Cancers, 2020, 12, 1687.	1.7	20
164	Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer. Frontiers in Immunology, 2020, 11, 572172.	2.2	21
165	Anti-Cancer Immunotherapies Targeting Telomerase. Cancers, 2020, 12, 2260.	1.7	34
166	Expression of the Reverse Transcriptase Domain of Telomerase Reverse Transcriptase Induces Lytic Cellular Response in DNA-Immunized Mice and Limits Tumorigenic and Metastatic Potential of Murine Adenocarcinoma 4T1 Cells. Vaccines, 2020, 8, 318.	2.1	2
167	Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy. Molecular Therapy, 2021, 29, 1199-1213.	3.7	16
168	GV1001 interacts with androgen receptor to inhibit prostate cell proliferation in benign prostatic hyperplasia by regulating expression of molecules related to epithelial-mesenchymal transition. Aging, 2021, 13, 3202-3217.	1.4	8

#	Article	IF	Citations
169	Telomerase as a Target for Therapeutic Cancer Vaccines and Considerations for Optimizing Their Clinical Potential. Frontiers in Immunology, 2021, 12, 682492.	2.2	18
170	Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduction and Targeted Therapy, 2021, 6, 263.	7.1	739
171	Tumorigenic effect of TERT and its potential therapeutic target in NSCLC (Review). Oncology Reports, 2021, 46, .	1.2	10
172	The Next-Generation of Combination Cancer Immunotherapy: Epigenetic Immunomodulators Transmogrify Immune Training to Enhance Immunotherapy. Cancers, 2021, 13, 3596.	1.7	12
173	CD4 Inhibits Helper T Cell Activation at Lower Affinity Threshold for Full-Length T Cell Receptors Than Single Chain Signaling Constructs. Frontiers in Immunology, 2020, 11, 561889.	2.2	3
174	Vaccine Approaches in Hepatocellular Carcinoma. , 2017, , 1-17.		1
175	Targeting Telomerase: Therapeutic Options for Cancer Treatment. , 2008, , 247-283.		4
177	Anti-cancer effect of GV1001 for prostate cancer: function as a ligand of GnRHR. Endocrine-Related Cancer, 2019, 26, 147-162.	1.6	9
178	Telomerase-based Cancer Therapeutics: A Review on their Clinical Trials. Current Topics in Medicinal Chemistry, 2020, 20, 433-457.	1.0	33
179	Potential Telomere-Related Pharmacological Targets. Current Topics in Medicinal Chemistry, 2020, 20, 458-484.	1.0	10
180	Telomerase activity: An attractive target for cancer therapeutics. World Journal of Pharmacology, 2014, 3, 86.	1.3	4
181	Non-small cell lung cancer: Emerging molecular targeted and immunotherapeutic agents. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1876, 188636.	3.3	27
183	Peptide-Based Active Immunotherapy in Cancer. Translational Medicine Series, 2008, , 109-130.	0.0	0
184	Therapeutic Targets and Drugs I: Telomerase and Telomerase Inhibitors. , 2009, , 225-249.		0
185	Role of Telomeres and Telomerase in Cancer. , 2009, , 171-180.		0
186	Cancer Prevention. Statistics in the Health Sciences, 2009, , 351-392.	0.2	0
187	Vaccine Therapy for Lung Cancer. , 2010, , 279-303.		1
188	Therapeutic Anticancer Approaches Targeting Telomerase and Telomeres. , 2015, , 295-309.		0

#	Article	IF	Citations
190	Mechanisms of telomere maintenance in pediatric brain tumors: Promising targets for therapy â€“ A narrative review. Glioma (Mumbai, India), 2020, 3, 105.	0.0	1
191	From bench to bedside: the growing use of translational research in cancer medicine. American Journal of Translational Research (discontinued), 2010, 2, 1-18.	0.0	59
192	Harnessing Antitumor CD4+ T Cells for Cancer Immunotherapy. Cancers, 2022, 14, 260.	1.7	26
194	A phase II study of chemotherapy in combination with telomerase peptide vaccine (GV1001) as second-line treatment in patients with metastatic colorectal cancer. Journal of Cancer, 2022, 13, 1363-1369.	1.2	4
195	Peptide-based delivery of therapeutics in cancer treatment. Materials Today Bio, 2022, 14, 100248.	2.6	24
196	Telomeres and Cancer. Life, 2021, 11, 1405.	1.1	11
203	Potential association factors for developing effective peptide-based cancer vaccines. Frontiers in Immunology, 0, 13, .	2.2	1
204	Safety, Immunogenicity, and 1-Year Efficacy of Universal Cancer Peptideâ€“Based Vaccine in Patients With Refractory Advanced Nonâ€“Small-Cell Lung Cancer: A Phase Ib/Phase IIa De-Escalation Study. Journal of Clinical Oncology, 2023, 41, 373-384.	0.8	11
205	A novel telomerase-derived peptide GV1001-mediated inhibition of angiogenesis: Regulation of VEGF/VEGFR-2 signaling pathways. Translational Oncology, 2022, 26, 101546.	1.7	4
207	A phase I/II escalation trial design T-RAD: Treatment of metastatic lung cancer with mRNA-engineered T cells expressing a T cell receptor targeting human telomerase reverse transcriptase (hTERT). Frontiers in Oncology, 0, 12, .	1.3	0
208	Telomerase: a good target in hepatocellular carcinoma? An overview of relevant preclinical data. Expert Opinion on Therapeutic Targets, 2022, 26, 767-780.	1.5	1
209	Immunotherapy and targeted therapy for lung cancer: Current status and future perspectives. Frontiers in Pharmacology, 0, 13, .	1.6	15
210	Therapeutic cancer vaccination against telomerase: clinical developments in melanoma. Current Opinion in Oncology, 2023, 35, 100-106.	1.1	0
211	Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers. Cancer and Metastasis Reviews, 2023, 42, 629-652.	2.7	13
218	The regulations of telomerase reverse transcriptase (TERT) in cancer. Cell Death and Disease, 2024, 15, .	2.7	0